Answer
Injection-site reactions are very common (≥1 in 10) with epcoritamab monotherapy, reported in 40% of the studied patients with relapsed or refractory large B-cell or follicular lymphoma after two or more lines of systemic therapy.
Sources for this answer
- Tepkinly 4 mg/0.8 ml solution for injectionAbbVie Ltd · emc · SmPC §4.8 Undesirable effects · Version 12Document updated
Sources checked